COMMUNIQUÉS West-GlobeNewswire

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21/02/2024
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and [...]
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
21/02/2024
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License [...]
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
21/02/2024
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings [...]
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
21/02/2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February [...]
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
21/02/2024
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the “Company”), a biotechnology company [...]
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
21/02/2024
EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will [...]
Two of Oregon’s Favorite Craft Breweries Team Up With the Portland Timbers as Official Craft Beer Sponsors
21/02/2024
10 Barrel Brewing and Widmer Brothers Sign a Multi-Year Deal That Includes Creation Of First Standing Room Only Section In The Stadium PORTLAND, Ore., Feb. 21, 2024 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co . (“10 Barrel [...]
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
21/02/2024
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. ( [...]
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference
21/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, [...]
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
21/02/2024
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 [...]
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
21/02/2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
21/02/2024
ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics’ New Capabilities for the First Time to Automate and Realize Efficiency Improvements for [...]
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
21/02/2024
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Evaxion annonce le succès des phases initiales de sa collaboration actuelle avec MSD dans le domaine des vaccins
21/02/2024
COPENHAGUE, Danemark, 21 févr. 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement [...]
Turnstone Biologics to Participate in Upcoming Investor Conferences
21/02/2024
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure [...]
Immuron Presentation Australian Biologics Festival 2024
21/02/2024
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development [...]
Introducing LQpay’s R2B2 - The Next Generation “Zero-Click Payment Solution,” Broadening Access for Dental Practices
21/02/2024
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- LQpay , a leader in innovative healthcare payments solutions, is proud to announce the launch of “R2B2,” the next generation of its exclusive Zero-Click Payment [...]
Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position
21/02/2024
BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and [...]
Bavarian Nordic delivered record financial results in 2023
21/02/2024
Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company’s history driven by extraordinary growth in travel health and a surge in smallpox/mpox vaccine sales. 2024 [...]

Pages